Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.

about

Oncolytic Virotherapy: A Contest between Apples and Oranges.Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

P2860

Q39230055-6C36D038-E6D4-41D5-8E58-7E7621560BF9 Q55447998-5CEAE605-0CFC-42B2-B512-0E0155A46D46

P2860

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.

Item

http://www.wikidata.org/entity/Q38924569

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.

@en

type

Item

label

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.

@en

prefLabel

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.

@en

P1476

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.

@en

P2093

Ennio Antonio Chiocca

http://www.w3.org/2001/XMLSchema#string

Hiroshi Nakashima

http://www.w3.org/2001/XMLSchema#string

Tran Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

Repressor element-1 silencing transcription factor/neuronal restrictive silencer factor (REST/NRSF) can regulate HSV-1 immediate-early transcription via histone modification

Oncolytic viruses as therapeutic cancer vaccines

The Sin3a repressor complex is a master regulator of STAT transcriptional activity

Functional interaction between class II histone deacetylases and ICP0 of herpes simplex virus type 1

HDAC6 is a microtubule-associated deacetylase

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization

The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction

Components of the REST/CoREST/histone deacetylase repressor complex are disrupted, modified, and translocated in HSV-1-infected cells

New viruses for cancer therapy: meeting clinical needs

P304

183-191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OV.S66081

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27512681

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

4918398

http://www.w3.org/2001/XMLSchema#string

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.

about

P2860

P2860

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932